Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Lung Cancer
Research explains why anticancer treatment effective for some, not others
April 6th, 2004
A new anticancer agent, gefinitib (Iressa), recently received U.S. Food and Drug Administration (FDA) approval for patients with advanced non-small-cell lung cancer (NSCLC) after a series of clinical trials and an expanded access program led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC). The compound is designed to target and block the activity of the tyrosine kinase enzyme that signals the epidermal growth factor receptor (EGFR), telling the cancer cells to grow, divide, and spread. Gefinitib shrunk tumors in only 10% of the NSCLC patients, although the enzyme is believed to be present and activated in most NSCLC patients. The results raised the...
Source: Cancer Weekly (2004-04-06)
|
